Target Validation Information
Target ID T32247
Target Name Calcitonin receptor
Target Type
Successful
Drug Potency against Target CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide Drug Info IC50 = 0.18 nM [526273]
CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide Drug Info IC50 = 0.377 nM [526273]
CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide Drug Info IC50 = 60 nM [526273]
CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide Drug Info IC50 = 0.249 nM [526273]
CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide Drug Info IC50 = 173 nM [526273]
CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide Drug Info IC50 = 5.39 nM [526273]
CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide Drug Info IC50 = 0.408 nM [526273]
CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide Drug Info Ki = 400 nM [526273]
CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide Drug Info IC50 = 0.326 nM [526273]
CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide Drug Info IC50 = 79 nM [526273]
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide Drug Info IC50 = 2450 nM [526273]
CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide Drug Info Ki = 2569 nM [526273]
CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide Drug Info IC50 = 1905 nM [526273]
References
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Ref 526273J Med Chem. 2002 Feb 28;45(5):1108-21.Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.